Peripheral blood stem cell

Anonymous. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies An individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005 23 5074-5087. 

Molineux G, Pojda Z, Hampson IN, Lord BI, Dexter TM. Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factor. 

Pelus LM, Horowitz D, Cooper SC, King AG. Peripheral blood stem cell mobilization. A role for CXC chemokines. Crit Rev Oncol Hematol 2002 43(3) 257-275. 

The bone marrow is not the only source of hematopoietic stem cells. Such cells are present in low numbers in peripheral blood, and these can be expanded in number with specific factors. Peripheral blood stem cells have the major therapeutic advantage that their harvest is relatively painless and less invasive. Likewise, umbilical cord stem cells can also be obtained in a non-invasive manner from... 

Stem cell therapy involves infusion of specialized cells utilized to perform specific functions. The traditional use of cell therapy includes harvest and cryopreservation of autologous hematopoietic cells either from the bone marrow (old approach) or mobilization and pheresis of hematopoietic stem cells from peripheral blood using stem cell-mobilizing cytokines such as hematopoietic colony-stimulating factors (G-CSF, GM-CSF) or chemokine inhibitors (AMD-3100). A more recent stem cell source is umbilical cord blood that has rich pleuripotent potential and can engraft at lower doses than bone marrow or mobilized peripheral blood stem cells. 

Mobilised peripheral blood stem cells are used as the source of stem cells for transplantation, moreover most allogeneic transplants now utilize peripheral blood rather than bone marrow A variety of mobilisation regimes are used but granulocyte colony-stimulating factor (G-CSF) is the most frequently In some cases G-CSF treatment of volunteers is involved researches ... 

Korbling M, Anderlini P, Hematology TA. Peripheral blood stem cell versus bone marrow allotransplantation does the source of hematopoietic stem cells matter Blood. 2001 98 2900 2908. 

Cutler C, Antin JH. Peripheral blood stem cells for allogeneic transplantation a review. Stem Cells. 2001 19 108-117. 

The feasibility and efficacy of granulocyte-colony stimulating factor (G-CSF) therapy and subsequent intracoronary infusion of collected peripheral blood stem cells were prospectively investigated in the MAGIC randomized clinical trial [137], which showed improved cardiac function and promotion of angiogenesis in myocardial infarction patients. 

However, the trial raised important safety questions. Intracoronary infusion of G-CSF-stimulated peripheral-blood stem cells apparently aggravated restenosis after coronary stenting, leading to early termination of the trial. Meanwhile, no temporal association between increased restenosis rate and stenting near the time of intracoronary cell administration has been noted in other studies that have not used G-CSF stimulation. 

Kang HJ, Kim HS, Zhang SY, Park KW, Cho HJ, Koo BK, Kim YJ, Soo Lee D, Soon DW, Han KS, Oh BH, Lee MM, Park YB. Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction the MAGIC cell randomised clinical trial. Lancet 2004 363 751-756. 

Harter C, Schulze B, Goldschmidt H, Benner A, Geiss HK, Hoppe-Tichy T et al. Piperachlin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or foUowing autologous peripheral blood stem cell transplantation a prospective randomized trial. Bone Marrow Transplant 2006 37 373-79. 

Pelus LM Peripheral blood stem cell mobilization New regimens, new cells, where do we stand. Curr Opin Hematol 2008 15 285. [PMID 18536564]... 

Theratope was given to patients with breast or ovarian cancer who received peripheral blood stem cell rescue after chemotherapy. Toxicity was mostly local. In vitro, NK activity which was low before immunization returned to normal values, toxicity against cells bearing sTn antigen appeared, and lymphocytes responded to sTn, by proliferation and IFN-y production. Antibodies against sTn were detected in 16 patients, while the anti-MUC-1 antibody titer decreased [210]. The remissions were longer in treated patients and there was a tendency to a decreased risk of relapse [211],... 

Weaver CH, Schulman KA, Wilson-Relyea B, Birch R, et al. 2000. Randomized trial of Filgrastim, Sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral blood stem cells. J Clin Oncol. 18 43-53. 

Reichardt, V. L., Okada, C. Y, Liso, A., Benike, C. J., Stockert-Goldstein, K. E., Engleman, E. G., Blume, K. G., and Levy, R. 1999. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma A feasibility study. Blood 93 2411-2419. 

Ren J, Ge L, Li Y, Bai J, Liu WC, Si XM. Detection of circulating CEA molecules in human sera and leukopheresis of peripheral blood stem cells with E. coli expressed bispecific CEAScFv-streptavidin fusion protein-based immuno-PCR technique. Ann NY Acad Sci 2001 945 116-118. 

Whole blood and blood components (e.g., platelets, red blood cells, granulocytes, and peripheral blood stems cells) present similar source product control issues and rely on similar control measures. The difference, of course, is that while a unit of blood is given to only one or possibly a few people, a single contaminated unit of source plasma could present significantly more widespread problems because it is blended with hundreds or thousands of plasma units to extract the ultrasmall quantities of plasma proteins in each unit. 

Guidance for Industry Cell Selection Devices for Point of Care Production of Minimally Manipulated Autologous Peripheral Blood Stem Cells (PBSCs)... 

Garrido SM, Chauncey TR. Neuroleptic malignant syndrome following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1998 21(4) 427-8. 

Gubbins PO, Penzak SR, Polston S, McConneh SA, Anaissie E. Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients. Pharmacotherapy 2002 22(8) 961-71. 

Colby C, McAfee S, Sackstein R, Finkelstein D, Fishman J, Spitzer T. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999 24(8) 897-902. 

Openshaw H, Lund BT, Kashyap A, Atkinson R, Sniecinski I, Weiner LP, Forman S. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning report of toxicity and immunological monitoring. Biol Blood Marrow Transplant 2000 6(5A) 563-75. 

Mugitani A, Yamane T, Park K, Im T, Tatsumi N, Tatsumi Y. Cardiac complications after high-dose chemotherapy with peripheral blood stem cell transplantation. J Jpn Soc Cancer Ther 1996 31 255-62. 

---